Type 1 Diabetes Clinical Trial
— REVERSIBLEOfficial title:
Towards Prevention of Mild-to-moderate Hypoglycemia in Type 1 Diabetes With Oral Glucose at a Higher Blood Glucose Threshold
NCT number | NCT04876079 |
Other study ID # | 2022-1119 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 1, 2021 |
Est. completion date | June 30, 2023 |
Verified date | August 2023 |
Source | Institut de Recherches Cliniques de Montreal |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
According to guidelines, when a mild-to-moderate hypoglycemia occurs (capillary blood glucose < 4.0 mmol/L), 15-20g of rapidly absorbed carbohydrates should be ingested. Patients should re-test and re-ingest 15-20g carbohydrates every 15 minutes until they recover from hypoglycemia. These recommendations were principally based on two studies conducted in the 80s before the introduction of intensive insulin therapy. In practice, only 32-50% of patients follow the current guidelines. In addition, recent studies suggest that under current intensive insulin therapies, an initial correction with 15g of oral glucose may be insufficient to rapidly correct mild-to-moderate hypoglycemia. With the development and increasing usage of newer glucose monitoring technologies, the community is witnessing a shift in hypoglycemia management, from a reactive to a proactive approach (e.g., prevent imminent episodes rather than treating established episodes).
Status | Completed |
Enrollment | 30 |
Est. completion date | June 30, 2023 |
Est. primary completion date | June 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Males and females = 18 years old 2. Clinical diagnosis of type 1 diabetes for at least one year 3. Treatment with multiple daily insulin injections or insulin pump therapy with insulin analogs (rapid, ultra-rapid and basal insulin) 4. A glycated hemoglobin A1c = 10% Exclusion Criteria: 1. Clinically significant microvascular complications: nephropathy (eGFR < 40 ml/min), severe proliferative retinopathy as judged by the investigator, neuropathy (particularly diagnosed gastroparesis) 2. Recent (< 3 months) acute macrovascular event (e.g., acute coronary syndrome or cardiac surgery) 3. Known significant cardiac rhythm abnormality based on investigator's judgement 4. Known significant neurological abnormality (e.g., seizure disorder) based on investigator's judgement 5. Ongoing pregnancy or breastfeeding 6. Severe hypoglycemia episode within 1 month of screening 7. Known uncorrected hypokalemia within the past 3 months (potassium < 3.5 mmol/L) |
Country | Name | City | State |
---|---|---|---|
Canada | Montreal Clinical Research Institute | Montreal | Quebec |
Lead Sponsor | Collaborator |
---|---|
Institut de Recherches Cliniques de Montreal |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time spent of glucose levels < 4.0 mmol/L | 60 minutes after carbohydrates consumption | ||
Secondary | Plasma glucose levels at 5 minutes after carbohydrates consumption | 5 minutes after carbohydrates consumption | ||
Secondary | Plasma glucose levels at 10 minutes after carbohydrates consumption | 10 minutes after carbohydrates consumption | ||
Secondary | Plasma glucose levels at 15 minutes after carbohydrates consumption | 15 minutes after carbohydrates consumption | ||
Secondary | Plasma glucose levels at 20 minutes after carbohydrates consumption | 20 minutes after carbohydrates consumption | ||
Secondary | Plasma glucose levels at 30 minutes after carbohydrates consumption | 30 minutes after carbohydrates consumption | ||
Secondary | Plasma glucose levels at 45 minutes after carbohydrates consumption | 45 minutes after carbohydrates consumption | ||
Secondary | Plasma glucose levels at 60 minutes after carbohydrates consumption | 60 minutes after carbohydrates consumption | ||
Secondary | Lowest plasma glucose level eached after CHO consumption | 60 minutes after carbohydrates consumption | ||
Secondary | Time from CHO consumption to the lowest plasma glucose level reached | 60 minutes after carbohydrates consumption | ||
Secondary | Time from CHO consumption to plasma glucose < 3.5 mmol/L | 60 minutes after carbohydrates consumption | ||
Secondary | Percentage of participants reaching hypoglycemia (< 4.0 mmol/L) after CHO consumption | 60 minutes after carbohydrates consumption | ||
Secondary | Percentage of participants for whom hypoglycemia was corrected at 10 minutes after CHO consumption | Only calculated for participants who will have glucose levels < 4.0 mmol/L | 10 minutes after carbohydrates consumption | |
Secondary | Percentage of participants for whom hypoglycemia was corrected at 15 minutes after CHO consumption | Only calculated for participants who will have glucose levels < 4.0 mmol/L | 15 minutes after carbohydrates consumption | |
Secondary | Percentage of participants for whom hypoglycemia was corrected at 20 minutes after CHO consumption | Only calculated for participants who will have glucose levels < 4.0 mmol/L | 20 minutes after carbohydrates consumption | |
Secondary | Percentage of participants for whom hypoglycemia was corrected at 25 minutes after CHO consumption | Only calculated for participants who will have glucose levels < 4.0 mmol/L | 25 minutes after carbohydrates consumption | |
Secondary | Percentage of participants for whom hypoglycemia was corrected at 30 minutes after CHO consumption | Only calculated for participants who will have glucose levels < 4.0 mmol/L | 30 minutes after carbohydrates consumption | |
Secondary | Percentage of participants for whom hypoglycemia was corrected at 35 minutes after CHO consumption | Only calculated for participants who will have glucose levels < 4.0 mmol/L | 35 minutes after carbohydrates consumption | |
Secondary | Percentage of hypoglycemic events that were corrected at 10 minutes after CHO consumption | Only calculated for events with glucose level < 4.0 mmol/L | 10 minutes after carbohydrates consumption | |
Secondary | Percentage of hypoglycemic events that were corrected at 15 minutes after CHO consumption | Only calculated for events with glucose level < 4.0 mmol/L | 15 minutes after carbohydrates consumption | |
Secondary | Percentage of hypoglycemic events that were corrected at 20 minutes after CHO consumption | Only calculated for events with glucose level < 4.0 mmol/L | 20 minutes after carbohydrates consumption | |
Secondary | Percentage of hypoglycemic events that were corrected at 25 minutes after CHO consumption | Only calculated for events with glucose level < 4.0 mmol/L | 25 minutes after carbohydrates consumption | |
Secondary | Percentage of hypoglycemic events that were corrected at 30 minutes after CHO consumption | Only calculated for events with glucose level < 4.0 mmol/L | 30 minutes after carbohydrates consumption | |
Secondary | Percentage of hypoglycemic events that were corrected at 35 minutes after CHO consumption | Only calculated for events with glucose level < 4.0 mmol/L | 35 minutes after carbohydrates consumption | |
Secondary | Percentage of participants requiring a second treatment with carbohydrates at 20 minutes after the first CHO consumption | Only calculated for participants who will have glucose levels < 4.0 mmol/L | 20 minutes after carbohydrates consumption | |
Secondary | Percentage of participants requiring a second treatment with carbohydrates at 40 minutes after the first CHO consumption | Only calculated for participants who will have glucose levels < 4.0 mmol/L | 40 minutes after carbohydrates consumption | |
Secondary | Percentage of participants requiring a second treatment with carbohydrates at 60 minutes after the first CHO consumption | Only calculated for participants who will have glucose levels < 4.0 mmol/L | 60 minutes after carbohydrates consumption | |
Secondary | Percentage of participants experiencing a rebound hyperglycemia (= 10.0 mmol/L) within the first hour following the first carbobydrates consumption | 60 minutes after carbohydrates consumption |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02855307 -
Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|